Feasibility of iFS™ for Intrastromal Arcuate Keratotomy (ISAK) Procedures

Not Applicable

Completed

• Conditions: Refractive Astigmatism
• Interventions: Device: iFS™ Femtosecond Laser System

• Registration Number: NCT01210820
• Lead Sponsor: Abbott Medical Optics

Brief Summary

The results of this trial will demonstrate that ISAK performed with the iFS™ femtosecond laser is a safe procedure.

Detailed Description

Surgeon will perform intrastromal arcuate keratotomy in arc segment patterns using the iFS™ femtosecond laser to treat subjects with refractive astigmatism.

Study Timeline

• Study Start: 2010-07
• Study First Submitted: 2010-09-24
• Study First Submitted QC: 2010-09-27
• Study First Posted: 2010-09-29
• Primary Completion: 2012-06
• Study Completion: 2012-06
• Results First Submitted: 2013-01-22
• Results First Submitted QC: 2013-03-14
• Status Verified: 2013-04
• Last Update Submitted: 2013-04-25
• Results First Posted: 2013-04-26
• Last Update Posted: 2013-05-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

1. Male or female, of any race, and at least 21 years of age at the time of the pre-operative examination and signing the consent form

2. Refractive error, no limitation on spherical refractive myopia or hyperopia and refractive astigmatism of 0.75 to 7.00 diopters (D) in the operative eye

3. Best Spectacle Corrected Distance Visual Acuity (BSCVA)

   • Group 1: Natural astigmatism, no cataract: BSCVA of 20/25 or better in both eyes
   • Group 1: Pre cataract surgery, no BSCVA criteria in the operative eye
   • Group 2: Post cataract surgery, BSCVA of 20/25 or better in both eyes

4. Uncorrected Visual Acuity (UCVA) of 20/40 or worse in the operative eye

5. Demonstration of agreement in the operative eye: Corneal astigmatism (as determined by keratometry) must be in agreement with refractive astigmatism (as determined by manifest refractions) as follows: Within ≤ 0.75 D in magnitude and within 15° axis when cylinder ≤ 1.5 D or 10° axis when cylinder > 1.5 D.

6. Preoperative central and peripheral (in planned treatment area) pachymetry of ≥ 500 um in the operative eye

7. Keratometry must be between 38.0 (flat) and 48.0 D (steep) in the operative eye

8. Corneal power (diopters) difference at the 3mm point from topographic center shall be ≤ 1D at the steepest meridian, by topography measurements in the operative eye

9. Intraocular pressure (IOP) of 12 to 21 mm Hg in the operative eye with no glaucomatous retinal changes

10. Stable refractive error in the operative eye, based on an exam (or prescription) at least 6 months prior to the pre-operative examination, and as compared to the pre-operative manifest refraction, must be ≤ 0.75 D (sphere and cylinder) and axis within 15 degrees for eyes with cylinder > 0.5D.

11. Subjects who have worn a contact lens in the operative eye within the past 30 days must remove the soft lens at least 2 weeks prior and a rigid or toric lens at least 3 weeks prior to baseline measurements. In addition, rigid or toric lens wearers must demonstrate stability in topography, keratometry and refraction before proceeding with surgery. Refractive stability is defined as a change of not more than 0.50 D in manifest sphere, cylinder, or keratometry (either axis) as compared to the unadjusted preoperative refraction in two visits at least one week apart.

12. Willing and capable of returning for follow-up examinations for the duration of the study

13. Subject must sign and be given a copy of the written Informed Consent Form

Exclusion Criteria

1. Abnormal topography, including evidence of keratoconus or pellucid marginal degeneration, in either eye
2. Irregular astigmatism in the operative eye
3. Evidence of clinically significant corneal opacity/scar in the operative eye within an 8 mm diameter zone of the visual axis
4. Women who are pregnant, breast-feeding, or intend to become pregnant over the course of the study, as determined by verbal inquiry
5. Concurrent use of topical or systemic medications that may impair healing, including but not limited to: antimetabolites, isotretinoin (Accutane®) within 6 months of treatment, and amiodarone hydrochloride (Cordarone®) within 12 months of treatment
6. History of any of the following medical conditions, or any other condition that could affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or herpes simplex, endocrine disorders (including, but not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid arthritis
7. History of active ophthalmic disease or other non-refractive abnormality (including, but not limited to, corneal dystrophy, symptomatic blepharitis, recurrent corneal erosion, dry eye syndrome, neovascularization > 1mm from limbus), retinal detachment/repair, at risk for developing strabismus, or with evidence of glaucoma or propensity for narrow angle glaucoma NOTE: Subjects with open angle glaucoma, regardless of medication regimen or control, or an IOP greater than 21 mm Hg at baseline, are specifically excluded from eligibility.
8. Known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course
9. Participation in any other conflicting ophthalmic drug or device clinical study during the period of participation in this clinical investigation -

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Natural Astigmatism	iFS™ Femtosecond Laser System	Subjects with refractive astigmatism and no prior history of ophthalmic surgery. May include subjects with cataracts.
Post cataract with residual astigmatism	iFS™ Femtosecond Laser System	Subjects who have had cataract removal surgery but have residual astigmatism.

Primary Outcome Measures

Name	Time	Method
Change in Refractive Astigmatism	6 months	Change in mean cylinder (assessed by manifest refraction) compared to baseline.
Change in Keratometric Cylinder	6 Months	Change in mean keratometric cylinder (as measured by keratometry) compared to baseline.

Trial Locations

Locations (1)

Paracelsus Medizinische Privat-Universitat, PMU; 🇦🇹 Salzburg, Austria